DGAP-News: MOLOGEN AG very successfully completes capital increase
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Capital Increase
MOLOGEN AG very successfully completes capital increase
01.02.2011 / 15:08
---------------------------------------------------------------------
- Private placement oversubscribed
- Significant amount of new shares subscribed by existing shareholders
- Proceeds of EUR 10 million for further development of product pipeline
Berlin, 02/01/2011 - Strong interest in shares of MOLOGEN AG: After all of
the 1,245,927 new shares were successfully placed, the company can close
the international private placement ahead of schedule on February 1st,
2011. More than 40% of the subscription rights of existing shareholders
were exercised. The shares offered in the context of the private placement
were significantly oversubscribed already on the first day. On basis of the
issue price of EUR 8.00 per share, MOLOGEN AG will receive approximately
EUR 10 million. The proceeds will be used for the further development of
the product pipeline.
'We are very pleased that we were able to successfully complete this
capital increase. The proceeds of this capital increase are now offering
scope for further development of our product pipeline. After the successes
with our colorectal cancer medication MGN1703, we want to take a broader
view going into the future and now also test its mode of action in
clinical trials for additional cancer indications', states Dr Matthias
Schroff, Research Chairman and Chairman of the Board of MOLOGEN AG. The
blockbuster candidate, the colorectal cancer medication MGN1703, is
supposed to be licensed this year.
The quirin bank AG was acting as lead manager in this capital increase.
About MOLOGEN AG
MOLOGEN AG, a German bio-pharmaceutical company based in Berlin,
specializes in the research and development of innovative medicaments based
on DNA structures. Activities focus on numerous product developments
relevant to the immune system, on the one hand vaccines against serious
infections and on the other hand cancer medicaments. MOLOGEN AG is one of
the few biotechnology companies worldwide with a well-compatible DNA-based
cancer treatment in the clinical development stage.
Stock in MOLOGEN AG is listed in the Prime Standard of the German stock
exchange (ISIN DE 0006637200).
Association memberships:
BIO Deutschland e.V. | DECHEMA - Gesellschaft für Chemische Technik und
Biotechnologie e.V. | Deutsche Industrievereinigung Biotechnologie (DIB)
| Stifterverband für die Deutsche Wissenschaft e.V. | Vereinigung
deutscher Biotechnologie-Unternehmen (VBU) | Verband Forschender
Arzneimittelhersteller e.V. (VFA) | Verband der Chemischen Industrie e.V.
(VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Hübner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
Jörg PetraßTel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations
Kirchhoff Consult AG
Janina Wismar M.A.
Tel: +49 - 40 - 60 91 86 - 50
Fax: +49 - 40 - 60 91 86 - 16
janina.wismar(at)kirchhoff.de
Note
This notification represents neither a request nor an offer to submit an
offer for the purchase of securities. This is particularly the case in the
USA and other countries or jurisdictions where an offer would be
unauthorized for thesubmission of a bid for the purchase or sale without
previous registration or authorization. The respective relevant legal
provisions concerning securities for these countries and jurisdictions
apply. This notification represents neither an offer for the sale of shares
without a par value attributed to the owner, nor a request to submit an
offer for the purchase of shares without a par value, but rather serves
solely to provide information.
Risk notice regarding forward-looking statements
Certain statements in this report contain forward-looking expressions or
corresponding expressions with negation or deviating versions thereof or
comparable terminology, these are designated as forward-looking statements.
In addition, all information given here that relates to planned or future
results from business sectors, financial figures, developments of the
financial situation or other financial figures or statistical statements,
contain such forward-looking statements. The company advises potential
investors to not rely on these forward-looking statements as a prediction
of actual future events. The company is not obliged to update these
forward-looking statements that only reflect the situation on the day of
publication, and rejects any liability therefor.
End of Corporate News
---------------------------------------------------------------------
01.02.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
110715 01.02.2011
Datum: 01.02.2011 - 15:08 Uhr
Sprache: Deutsch
News-ID 33111
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG very successfully completes capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
